Investor Relations

Whether you're interested in investing and/or partnering, we're here to help you understand our work and objectives.

Investor PresentationResearch & Pipeline →
Market Opportunity

LPR is estimated to affect more than 20% of the United States population.

N-Zyme Biomedical seeks to provide much-needed treatments for the millions of people in the US and worldwide that suffer from LPR.

$26 Billion/Year Spent On PPIs For LPR
PPI Placebo-Controlled Trials Failed To Demonstrate Efficacy
No Medical Therapy Currently Available
Multiple Patent Applications Filed
FDA/IND Phase III Clinical Trial Approval Received
Institutional Review Board (IRB) Phase III Clinical Trial Approval Received
Regulatory Approvals & High-value IP

The disclosure provides a composition comprising of an inhaled and oral sustained-release formulation of an HIV protease inhibitor capable of inhibiting pepsin and a pharmaceutically acceptable carrier.

Request Investor Presentation for details  →

Excellence in leadership

Founded by Franco Vigile, an enterpreneur, and Nikki Johnston, Ph.D., who dedicated her career to LPR research.

Meet our team

Request investor package

Enter your email information to receive our investor presentation.

Send Request
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Press Releases
July 28, 2022
N-Zyme files patent for new, sustained-release oral fosamprenavir formulation for the treatment of reflux.

N-Zyme is very pleased to announce that it’s Chief Scientific Officer, Dr. Nikki Johnston, and Chief Executive Officer, Franco Vigile, have filed a U.S. Patent Application: 63/392,929, Sustained-release oral fosamprenavir for the treatment of reflux on July 28, 2022. 

June 24, 2021
FDA/IND Phase Ill Clinical Trial Approval received

The Medical College of Wisconsin received a "Study May Proceed" letter from The Center for Drug Evaluation and Research in the FDA approving their IND 149546 to assess the efficacy of fosamprenavir/Lexiva for the treatment of LPR in a phase Ill clinical trial. *An IND amendment request will be submitted for use of our sustained-release oral fosamprenavir formulation that is currently under development.

May 8, 2021
The Medical College of Wisconsin IRB has approved the Phase Ill Clinical Trial

The Medical College of Wisconsin Institutional Review Board (IRB) has approved the 12-week randomized, double-blinded, placebo-controlled clinical trial to assess the efficacy of fosamprenavir/Lexiva for LPR, Protocol ID: PRO00037954.

April 16, 2021
International Patent Filed by the Medical College of Wisconsin

International Patent Application: PCT/US2021/027758, Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux, was filed by the Medical College of Wisconsin on April 16, 2021. Nikki Johnston is the sole named inventor on that patent. Claims include use of HIV inhibitors for reflux (LPR, GERD, and airway reflux), by both local/inhaled and oral/systemic delivery.

Previous Releases →
© 2021 N-Zyme Biomedical Inc.
All Rights Reserved